Saha Debabrata, Sekhar Konjeti R, Cao Carolyn, Morrow Jason D, Choy Hak, Freeman Michael L
Departments of Radiation Oncology , Vanderbilt University Medical Center, Vanderbilt University Ingram Cancer Center, Nashville, Tennessee 37232, USA.
Cancer Res. 2003 Oct 15;63(20):6920-7.
Increased expression of cyclooxygenase (COX) 2 and the production of PGs appear to provide a survival advantage to transformed cells through the inhibition of apoptosis, increased attachment to extracellular matrix, increased invasiveness and the stimulation of angiogenesis. The purpose of this study was to determine whether an angiogenic antagonist, SU5416, could inhibit endogenous and phorbol 12-myristate 13-acetate (PMA)-mediated induction of COX-2 expression. SU5416 (5 micro M) inhibited endogenous as well as PMA-mediated induction of COX-2 expression when analyzed by immunoblot and Northern blot analysis. However, COX-1 expression remained unchanged under similar conditions. PMA is a potent inducer of reactive oxygen species that can play an important role during the induction of COX-2 expression. Our results demonstrated that PMA-mediated induction of COX-2 expression was found to be dependent on NADPH oxidase activity. An inhibitor of NADPH oxidase (diphenyleneiodonium chloride) blocked the PMA-mediated induction of COX-2 expression. The oxidase complex exhibited a temporal pattern of activation after exposure to PMA in which maximum activation was observed at 30 min after the addition of PMA. Activation of NADPH oxidase was also inhibited by SU5416, whereas an inhibitor of epidermal growth factor receptor signaling was unable to prevent the PMA-mediated induction of NADPH oxidase activity. When we blocked the PMA-mediated production of reactive oxygen species by blocking NADPH oxidase with SU5416, COX-2 expression and PGE(2) synthesis were also inhibited. Our results suggest that inhibition of NADPH oxidase activity, blocking of COX-2 expression, and PGE(2) synthesis may represent novel targets for SU5416.
环氧化酶(COX)-2表达的增加和前列腺素(PGs)的产生似乎通过抑制细胞凋亡、增加与细胞外基质的附着、增强侵袭性以及刺激血管生成,为转化细胞提供生存优势。本研究的目的是确定血管生成拮抗剂SU5416是否能抑制内源性和佛波酯12-肉豆蔻酸酯13-乙酸酯(PMA)介导的COX-2表达诱导。通过免疫印迹和Northern印迹分析,SU5416(5微摩尔)抑制了内源性以及PMA介导的COX-2表达诱导。然而,在类似条件下COX-1表达保持不变。PMA是活性氧的强效诱导剂,在COX-2表达诱导过程中可发挥重要作用。我们的结果表明,PMA介导的COX-2表达诱导依赖于NADPH氧化酶活性。NADPH氧化酶抑制剂(二苯基碘鎓氯化物)阻断了PMA介导的COX-2表达诱导。氧化酶复合物在暴露于PMA后呈现出时间性激活模式,在添加PMA后30分钟观察到最大激活。SU5416也抑制了NADPH氧化酶的激活,而表皮生长因子受体信号抑制剂无法阻止PMA介导的NADPH氧化酶活性诱导。当我们用SU5416阻断NADPH氧化酶来阻断PMA介导的活性氧产生时,COX-2表达和前列腺素E2(PGE2)合成也受到抑制。我们的结果表明,抑制NADPH氧化酶活性、阻断COX-2表达和PGE2合成可能是SU5416的新靶点。